– Expect to report topline data from the Seabreeze STAT COPD study in 1H 2026 – SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announced the initiation of its Phase 2 Seabreeze STAT COPD study (NCT06940154) following written agreement on the final study protocol f ...

Enrollment and dosing underway in Phase 3 clinical trial (the “MIRACLE” trial) evaluating Annamycin (naxtarubicin) for the treatment of R/R AML Regulatory and site selection progress to date supports interim data readout expected in the second half of 2025 Recently received European Medicines Agency (EMA) approval adds nine additional countries to the Company’s ongoing MIRACLE trial; Authorization granted in all EU countries requested Company to host conference call and webcast today, May 14th at 8:30 AM E ...

Lexicon Pharmaceuticals (LXRX) Q1 2025 Earnings Call May 13, 2025 05:00 PM ET Company Participants Lisa DeFrancesco - SVP of Investor Relations & Corporate CommunicationsMike Exton - CEO & DirectorScott Coiante - SVP and CFOAndrew Tsai - SVPCraig Granowitz - SVP & Chief Medical OfficerYigal Nochomovitz - DirectorLander Egaña-Gorroño - Senior Associate, Biotech Equity Research Conference Call Participants Roanna Ruiz - Senior Managing Director, Biotechnology AnalystYasmeen Rahimi - Sr. Research Analyst Opera ...

Lexicon Pharmaceuticals (LXRX) Q1 2025 Earnings Call May 13, 2025 05:00 PM ET Speaker0 Welcome to the Lexicon Pharmaceuticals First Quarter twenty twenty five Financial Results Conference Call. At this time, all participants are in a listen only mode. Following management's prepared remarks, we will hold a brief question and answer session. As a reminder, this call is being recorded today, 05/13/2025. I will now turn the call over to Lisa DiFrancesco, SVP, Investor Relations and Corporate Communications for ...

Company had a strong start to 2025, emerging as an R&D-focused organization Exclusive license agreement with Novo Nordisk for LX9851 executed; IND-enabling studies on track for completion in 2025 Phase 2b PROGRESS study confirmed 10 mg pilavapadin as appropriate dose for advancement into Phase 3 development for diabetic peripheral neuropathic pain Conference call and webcast at 5:00 pm ET THE WOODLANDS, Texas, May 13, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported fin ...

SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that its stockholders voted to approve all proposals required to be approved in connection with the pending merger with ACELYRIN, INC. (Nasdaq: SLRN) at its Special Meeting of Stockholders. Martin Babler, P ...

The bear market induced by the Federal Reserve’s monetary tightening officially ended in 2023, but it seems no one remembered to tell the biotech sector. Biotech stocks lagged the broader market in 2023 and 2024, and the SDPR S&P Biotech ETF NYSE: XBI is trading at the same level as in 2017. While biotech stocks soared during the COVID-19 pandemic, investors now view the sector skeptically. Can battered biotech stocks rebound in 2025? While the broader sector may look scary, some companies are making progre ...

Neumora Therapeutics (NMRA) Q1 2025 Earnings Call May 12, 2025 04:30 PM ET Company Participants Helen Rubinstein - VP-IR and Corporate CommunicationsPaul Berns - Co-Founder, Executive Chairman and Chief Executive OfficerJoshua Pinto - PresidentBill Aurora - Chief Operating & Development OfficerMichael Milligan - CFODouglas Tsao - Managing DirectorBrian Abrahams - MD & Global Sector Head - Health Care ResearchGraig Suvannavejh - Managing DirectorJohn Boyle - Biotechnology Equity Research AssociatePoorna Kann ...

Neumora Therapeutics (NMRA) Q1 2025 Earnings Call May 12, 2025 04:30 PM ET Speaker0 Ladies and gentlemen, thank you for standing by. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. Please be advised that today's conference is being recorded. I would now like to turn the conference over to Helen Rubinstein, Vice President of Investor Relations and Communications. Please go ahead. Speaker1 Good afternoon, and thank you fo ...

KEY HIGHLIGHTS First patient expected to start therapy by end of Q2-2025 in Phase 2a proof-of concept clinical trial for Cholesterol Efflux MediatorTM VAR 200 in patients with diabetic kidney disease (DKD).Obesity-associated cardiometabolic preclinical proof-of-concept study with Inflammasome ASC Inhibitor IC 100 planned to begin by end of Q2-2025.Investigational New Drug Application (IND) for IC 100 anticipated to be submitted H2-2025, followed by initiation of a Phase 1 clinical trial in healthy overweigh ...